艾伯维拟以高达21亿美元收购细胞疗法开发商Capstan

格隆汇
01 Jul

美国制药商艾伯维周一表示,将以高达21亿美元的现金交易收购细胞疗法开发商Capstan Therapeutics。Capstan开发CAR-T疗法,是一种利用患者自体免疫细胞,特别是T细胞对抗疾病的疗法;其主要药物CPTX2309目前正在开发中,用于治疗自体免疫疾病。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10